Chronic Treatment with Glucagon-Like Peptide-1 and Glucagon Receptor Co-Agonist Causes Weight Loss-Independent Improvements in Hepatic Steatosis in Mice with Diet-Induced Obesity

Emma Rose McGlone,Iona Davies,Marian Dore,Rob Goldin,Ben Jones,Zhigang Liu,Jia V. Li,Panagiotis A. Vorkas,Bernard Khoo,David Carling,James Minnion,Stephen R. Bloom,Tricia M. -M. Tan

BIOMEDICINE & PHARMACOTHERAPY（2024）

Cited 0|Views23

Key words

Metabolic dysfunction-associated steatotic liver disease (MASLD),non-alcoholic Fatty Liver Disease (NAFLD),weight loss,type 2 diabetes mellitus,glucagon,glucagon-like peptide-1

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined